Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy
Open Access
- 1 January 2022
- journal article
- review article
- Published by XMLink in The World Journal of Men's Health
- Vol. 40 (1) , 74-86
Abstract
Casado E, et al. World J Mens Health. 2022 Jan;40(1):74-86. https://doi.org/10.5534/wjmh.210061Keywords
This publication has 39 references indexed in Scilit:
- Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and ControversiesInternational Journal of Endocrinology, 2015
- Mortality following Hip Fracture in Men with Prostate CancerPLOS ONE, 2013
- Causes, consequences, and treatment of osteoporosis in menDrug Design, Development and Therapy, 2013
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Fracture risk in men with prostate cancer: A population-based studyJournal of Bone and Mineral Research, 2011
- Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survivalAge and Ageing, 2010
- Long‐term changes in bone mineral density and predicted fracture risk in patients receiving androgen‐deprivation therapy for prostate cancer, with stratification of treatment based on presenting valuesBJU International, 2009
- Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancerCancer, 2009
- Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate CancerUrology, 2007
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993